Wim Parys, M.D., obtained his medical degree from the Katholieke Universiteit Leuven, Belgium. He was in private practice for nine years before joining the Janssen Research Foundation in Beerse, Belgium, where he held several R&D positions and developed a drug for Alzheimer’s disease.
In 2000 Wim became the Head of Development at the biotech company Tibotec and relocated to the United States to establish Tibotec Inc., the U.S.-based subsidiary. Under his tenure, Tibotec (then acquired by Johnson & Johnson) developed and launched three innovative HIV drugs.
As Development Head of Janssen’s Infectious Diseases & Vaccines therapeutic area, he led the discovery and development of other medicines for HIV, Hepatitis C, multi-drug resistant tuberculosis and respiratory viral diseases.
In 2013 Wim became the R&D head of the newly established Global Public Health group at Janssen.